 |
Talon Therapeutics, Inc. Reports First Quarter 2012 Financial Results
May 15, 2012
|
29.2 KB |
|
| |
SAN MATEO, Calif., May 15, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three months ended March 31, 2012.
"In the first quarter, the Oncologic Drugs Advisory Committee (ODAC) affirmed evidence from clinical studies that support the use of Marqibo® for a very rare patient pop...
|
|
Talon Therapeutics to Host a Conference Call to Report First Quarter 2012 Financial Results and Business Update on May 15, 2012
May 11, 2012
|
18.5 KB |
|
| |
SAN MATEO, Calif., May 11, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Tuesday, May 15, 2012 at 9:00AM PDT, to discuss first quarter 2012 financial results and provide a business update.
Conference call details:
Date:
Tuesday, May 15, 2012
...
|
|
Talon Therapeutics Receives Notification of Three Month PDUFA Date Extension for Marqibo(R)
May 7, 2012
|
21.7 KB |
|
| |
SAN MATEO, Calif., May 7, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that its New Drug Application (NDA) seeking accelerated approval of Marqibo® has been given a three-month Prescription Drug User Fee Act (PDUFA) date extension to Aug...
|
|
Talon Therapeutics Appoints Howard Pien to Board of Directors
Apr 24, 2012
|
25.4 KB |
|
| |
SAN MATEO, Calif., April 24, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of can...
|
|
Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2011 Financial Results
Mar 29, 2012
|
31.6 KB |
|
| |
SAN MATEO, Calif., March 29, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the fourth quarter and year ended December 31, 2011, and provided a corporate update.
"Our primary corporate focus for the past year has been the development of Marqibo with the objective of receiving FDA approv...
|
|
Talon Therapeutics to Host a Conference Call to Report 2011 Financial Results and Business Update on March 29, 2012
Mar 26, 2012
|
18.4 KB |
|
| |
SAN MATEO, Calif., March 26, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Thursday, March 29, 2012 at 10:00AM PDT, to discuss fourth quarter and full year 2011 financial results and provide a business update.
Conference call details:
Date:
Thursday, ...
|
|
Talon Therapeutics' Product Candidate Marqibo(R) Receives a Positive Vote From the Oncologic Drugs Advisory Committee (ODAC)
Mar 21, 2012
|
21.3 KB |
|
| |
SAN MATEO, Calif., March 21, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), announced the Oncologic Drugs Advisory Committee voted 7 yes, 4 no, and 2 abstain that evidence from clinical studies supports a favorable benefit/risk assessment for use of Marqibo® (vincristine sulfate liposomes injection) seeking the indication for...
|
|
Talon Therapeutics to Host a Conference Call on March 22, 2012 to Discuss the Results of the ODAC Meeting on Marqibo(R)
Mar 20, 2012
|
20.3 KB |
|
| |
SAN MATEO, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Thursday, March 22, 2012 at 9:00AM PT, to discuss the outcome of the Oncologic Drugs Advisory Committee (ODAC) Meeting on Marqibo.
Conference call details:
Date:
Thursday, March...
|
|
Talon Therapeutics' Product Candidate Marqibo(R) to be Assessed by Oncologic Drug Advisory Committee (ODAC) on March 21, 2012 With a PDUFA Date of May 13, 2012
Feb 3, 2012
|
68.3 KB |
|
| |
SAN MATEO, Calif., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc. (OTCBB:TLON) announced Marqibo® (vincristine sulfate liposomes injection) is scheduled to be assessed by ODAC on Wednesday, March 21, 2012. Talon's New Drug Application (NDA) for Marqibo was accepted for filing by the FDA and is being reviewed under Subpart H — A...
|
|
Talon Therapeutics Announces $11M Financing
Jan 9, 2012
|
22.4 KB |
|
| |
SAN MATEO, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management, its largest shareholders, for the sale of $11 million in preferred stock. Talon intends to use the net proceeds from the financing to advance its cl...
|
|
Talon Therapeutics Announces First Patient Enrolled in the Phase 3 OPTIMAL>60 Study of Marqibo(R) in Adult Patients With Newly Diagnosed, Aggressive Non-Hodgkin's Lymphoma
Nov 29, 2011
|
23.2 KB |
|
| |
Conducted by the prestigious German High-Grade NHL Study Group
R-CHMP-14 (M=Marqibo) versus R-CHOP-14 (O=standard vincristine)
Powered to demonstrate superior progression-free survival of R-CHMP-14
SAN MATEO, Calif., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the enrollmen...
|
|
Talon Therapeutics, Inc. Reports Third Quarter 2011 Financial Results
Nov 14, 2011
|
36.1 KB |
|
| |
SAN MATEO, Calif., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and nine months ended September 30, 2011.
"In the third quarter of 2011, we achieved two significant accomplishments: the acceptance for filing of our NDA seeking accelerated approval of Marqibo® a...
|
|
Talon Therapeutics to Host a Conference Call to Report Third Quarter 2011 Financial Results and Business Update on November 15, 2011
Nov 11, 2011
|
22.6 KB |
|
| |
SAN MATEO, Calif., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Tuesday, November 15, 2011 at 9:00AM PT, to include a discussion of financial results and highlights of the third quarter and a business update.
Conference call details:
Date:
Tu...
|
|
Talon Therapeutics' New Drug Application for Marqibo(R) Accepted for Filing by the United States Food and Drug Administration
Sep 27, 2011
|
68.6 KB |
|
| |
Accelerated approval review path confirmed by the FDA
Prescription Drug User Fee Act (PDUFA) date set for May 13, 2012
SAN MATEO, Calif., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) announced its new drug application (NDA) seeking accelerated approval of Marqibo® (vincristine sulfate liposomes...
|
|
Talon Therapeutics Receives Special Protocol Assessment Agreement from the Food and Drug Administration for Its Phase 3 Confirmatory Study of Marqibo(R) in Newly Diagnosed Acute Lymphoblastic Leukemia
Aug 29, 2011
|
73.7 KB |
|
| |
SAN MATEO, Calif., Aug. 29, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), announced today the company has reached agreement with the U. S. Food and Drug Administration (FDA) regarding a special protocol assessment (SPA) for its planned Phase 3 study of Marqibo® (vincristine sulfate liposomes injection) in adults with newly d...
|
|
Talon Therapeutics, Inc. Reports Second Quarter 2011 Financial Results
Aug 15, 2011
|
35.3 KB |
|
| |
SAN MATEO, Calif., Aug. 15, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and six months ended June 30, 2011.
"Submitting our new drug application for Marqibo® was a momentous event for Talon. It was the culmination of exceptional dedication on the part of our employees ...
|
|
Talon Therapeutics to Host a Conference Call to Report Second Quarter 2011 Financial Results and Business Update on August 15, 2011
Aug 9, 2011
|
23.1 KB |
|
| |
SAN MATEO, Calif., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Monday, August 15, 2011 at 8:30AM PT, to include a discussion of results and highlights of the second quarter and a business update.
Conference call details:
Date:
Mond...
|
|
Talon Therapeutics Announces First Patient Enrolled in National Cancer Institute Phase 1 Trial of Marqibo(R) in Children and Adolescents
Jul 20, 2011
|
26.0 KB |
|
| |
SAN MATEO, Calif., July 20, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the enrollment of the first patient in a Phase 1 trial to evaluate the safety, activity and pharmacokinetics of Marqibo® (vincristine sulfate liposomes injection) in children and adolescents with relapsed or refractory cancer being conduc...
|
|
Talon Therapeutics Submits New Drug Application for Marqibo(R)
Jul 18, 2011
|
70.7 KB |
|
| |
SAN MATEO, Calif., July 18, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced its New Drug Application (NDA) for Marqibo (vincristine sulfate liposomes injection) was submitted to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of Marqibo in adult Ph- ALL, in second or greater relapse or that ha...
|
|
Talon Therapeutics Provides NDA Submission Timeline Update for Marqibo(R)
Jun 30, 2011
|
25.2 KB |
|
| |
SAN MATEO, Calif., June 30, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today provided an update of the status of its planned NDA submission for Marqibo ((vincristine sulfate liposomes injection).
"I am pleased to announce that all of the Non-Clinical, Clinical and Quality (Chemistry, Manufacturing and Controls) modules o...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
RSS News Feeds